Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Increased Levothyroxine Requirement After Tirzepatide Initiation.

Created on 04 Nov 2026

Authors

Derya Koç, Miraç Vural Keskinler

Published in

AACE endocrinology and diabetes. Volume 13. Issue 5. Pages 677-678. Epub Apr 18, 2026.

Abstract

Dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists such as tirzepatide are increasingly used for obesity management. These agents delay gastric emptying and may influence the absorption of orally administered drugs, including levothyroxine.
A 48-year-old woman with class I obesity (BMI 32 kg/m2) was diagnosed with overt primary hypothyroidism (TSH 17.1 mIU/L; free T4 0.76 ng/dL). Levothyroxine 25 μg/d achieved biochemical normalization. Tirzepatide 2.5 mg weekly was initiated for weight management. Over 3 months, body weight decreased from 116 kg to 100 kg (-13.8%). Despite confirmed adherence and absence of interacting medications, TSH increased to 20.7 mIU/L with low-normal free T4. Levothyroxine dose was increased to 50 μg/d, resulting in TSH suppression (0.33 mIU/L).
Weight loss is typically associated with reduced levothyroxine requirements; however, this case demonstrated the opposite pattern. Tirzepatide-induced delay in gastric emptying may have impaired levothyroxine absorption. Previous reports with glucagon-like peptide-1 receptor agonists have mainly described reduced levothyroxine requirements, suggesting that this interaction may be variable and patient-specific.
Levothyroxine requirements may increase in some patients following tirzepatide initiation. Clinicians should consider reassessing thyroid function within 6-8 weeks after starting dual incretin therapy.

PMID:
42978782
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement